ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

HEMO Hemogenyx Pharmaceuticals Plc

1.76
-0.0025 (-0.14%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0025 -0.14% 1.76 1.73 1.76 1.75 1.73 1.74 7,822,292 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.98M -0.0035 -4.97 19.87M

Hemogenyx Pharmaceuticals PLC Admission of Shares to Official List (2080P)

07/02/2023 2:30pm

UK Regulatory


Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart


From Mar 2022 to Mar 2024

Click Here for more Hemogenyx Pharmaceuticals Charts.

TIDMHEMO

RNS Number : 2080P

Hemogenyx Pharmaceuticals PLC

07 February 2023

7 February 2023

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Admission of Shares to Official List

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has applied to the Financial Conduct Authority to admit 2 ordinary shares of 1 pence each in the Company to the Official List in relation to a historical transaction. It is expected that the shares will be admitted on or around 8 February 2023. The total issued share capital of the Company will remain 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury.

Enquiries:

 
 Hemogenyx Pharmaceuticals plc           https://hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive 
  Officer & Co-Founder                   headquarters@hemogenyx.com 
 Peter Redmond, Director                 peter.redmond@hemogenyx.com 
 
                                         Tel: +44 (0)20 3470 
 SP Angel Corporate Finance LLP           0470 
 Matthew Johnson, Vadim Alexandre, 
  Adam Cowl 
 
                                         Tel: +44 (0)20 7469 
 Peterhouse Capital Limited               0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSZZGGZDNFGFZM

(END) Dow Jones Newswires

February 07, 2023 09:30 ET (14:30 GMT)

1 Year Hemogenyx Pharmaceuticals Chart

1 Year Hemogenyx Pharmaceuticals Chart

1 Month Hemogenyx Pharmaceuticals Chart

1 Month Hemogenyx Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock